Polymorphic Analysis: Identification and Risk Assessment of Crystalline Forms
Polymorphic analysis is the identification, comparison and risk assessment of the different crystalline forms an API can adopt, each with its own solubility, stability and processing behaviour. The study combines XRD, DSC, TGA and complementary techniques to determine which form is present, whether it is the thermodynamically stable one, and what impact that has on bioavailability, manufacturing and intellectual property.
What is polymorphic analysis?
Polymorphism is the ability of a single chemical compound to arrange itself in more than one crystalline structure, each with its own lattice energy, melting point, solubility and stability, while sharing the identical molecular formula. Solvates, hydrates and the amorphous state are not polymorphs in the strict sense, but they share the same practical consequence: different physicochemical properties arising from the same molecule.
The pharmaceutical relevance comes from the fact that the solid form can determine whether a drug dissolves, absorbs and stays within specification over shelf life. The most cited case is ritonavir: in 1998, a new polymorphic form (Form II), far less soluble than the original form, appeared spontaneously during commercial manufacturing and led to the product's withdrawal from the market, with no change to the formulation itself.
The analysis combines two layers: a risk assessment, which weighs the synthesis route, the patent history and available literature to decide whether the compound carries meaningful polymorphic potential, and an analytical layer, multi-technique characterization by XRD, DSC, TGA and complementary methods, when the identified risk calls for experimental confirmation of which form is present and its relative stability.
What polymorphism affects, and why it matters
The same molecule, in different crystalline forms, can behave like distinct products from the standpoint of performance, manufacturing and intellectual property.
| Property | What changes | Practical consequence |
|---|---|---|
| Solubility and dissolution rate | A different crystal lattice energy changes how fast the drug dissolves in the biological medium. | Can shift Cmax and Tmax and jeopardize bioequivalence, particularly for low-solubility APIs (BCS II and IV). |
| Physicochemical stability | A metastable form can spontaneously convert to the thermodynamically more stable form over storage. | Can cause a specification failure, or a change in dissolution or appearance mid-shelf-life, with no formulation failure involved. |
| Manufacturability | Crystal form, crystal habit and hygroscopicity affect powder flow, compressibility and drying behaviour. | Can produce process failures — capping, sticking, weight variation — wrongly attributed to formulation causes. |
| Intellectual property | A specific crystalline form can be the subject of a patent separate from the parent molecule. | An unidentified form in your own product, or a competitor's, can create patent litigation exposure or block a launch. |
| Regulatory equivalence | Reference and generic products must demonstrate equivalence in the solid-state properties that affect performance. | An undocumented form difference can stall registration or ANDA approval and trigger an additional study requirement. |
Not every polymorphic change has a practical consequence: impact depends on how far the affected property drifts from the acceptable range for that product and route of administration. The risk assessment in the study defines which properties need experimental verification in each case.
From technique to decision
Method choice depends on the analytical question, the sample matrix and the development stage. No technique enters the scope without answering a question the risk assessment raised.
| Technique | What it measures | What decision it supports |
|---|---|---|
| XRD / PXRD | The sample's diffraction pattern, reflecting the periodic arrangement of the crystal lattice. | Whether two samples share the same crystalline form or whether a new form is present. |
| DSC | Thermal events such as melting, recrystallization, glass transition and exothermic or endothermic polymorphic conversion. | Whether a thermal event indicates a distinct polymorph, a solvate/hydrate, or amorphous content. |
| TGA | Mass loss as a function of temperature, associated with volatiles, water or solvent of crystallization. | Whether an event observed by DSC is a genuine solid-solid transition or desolvation/dehydration. |
| Hot-stage polarized light microscopy | Visual change in crystal morphology and birefringence across a controlled temperature ramp. | Whether the thermal event recorded by DSC corresponds to an observable phase transition, melting or recrystallization. |
| Confocal Raman spectroscopy | The vibrational signature specific to each form, at micron scale and without extensive sample preparation. | Which form is present in a given particle, tablet region or blend, without requiring API isolation. |
| Intrinsic dissolution rate and stress studies | Dissolution rate per unit surface area under controlled hydrodynamics, and interconversion behaviour under temperature, humidity or competitive slurry. | Whether the form difference translates into a meaningful solubility difference, and which form is thermodynamically stable under storage conditions. |
The analytical workflow
Every product runs through the same logical sequence, with analytical scope adjusted to the risk identified at the first stage; not every product assessed needs a full forensic comparison.
Documentary risk assessment and screening (ICH Q6A)
Critical review of the API's synthesis route, patent history and available literature, following the logic of the ICH Q6A decision tree for polymorphism. Classifies whether the compound carries meaningful polymorphic potential before any bench assay.
Risk assessment report / ICH Q6A decision-tree memorandum
Form identification and characterization
Multi-technique characterization by XRD, DSC, TGA, microscopy and Raman, where applicable, of the samples under study, to identify the form present and distinguish crystallinity, amorphous content, solvate or hydrate.
A characterization profile per form: XRD pattern, thermal signature and, where applicable, Raman spectrum
Comparison and stability study
Comparison of the identified form against the reference product or prior batches, and stress testing (temperature, humidity, competitive slurry) to determine relative thermodynamic stability and interconversion risk.
Comparative report and interconversion risk assessment
Interpretation and regulatory/IP support
Comparison of results against regulatory expectations (ICH Q6A, USP <941>) and, where applicable, the patent landscape, with discussion of the practical impact on bioavailability, manufacturability or stability, and evidence organized for submission or intellectual-property use.
An interpreted report, with a technical opinion
Applications
The same analytical capability supports distinct fronts of risk and decision, from development through regulatory defense.
Generics & similars
Solid-form equivalence in the registration dossier
Evidence that the generic's crystalline form is equivalent to the reference product in the properties that affect performance, avoiding the historical scenario of a bioavailability failure caused by a different form.
Formulation R&D
Form selection ahead of development
Selecting the form with the best solubility and stability before committing the manufacturing process to a metastable or low-solubility form.
CDMO & contract manufacturers
Process-deviation investigation
Identifying an unintended form conversion during granulation, drying, milling or compression, when a batch performs outside expectations with no change in composition.
Intellectual property
Support for disputes or freedom-to-operate
Characterizing the crystalline form present in your own product or a third party's to support or challenge a form-specific patent claim.
What you receive
An interpreted technical report, not a set of loose diffractograms.
Data and evidence
- X-ray diffractograms (XRD/PXRD) indexed by sample and form
- DSC and TGA thermograms with events identified
- Polarized light micrographs and, where applicable, hot-stage data
- Raman spectra per form, where applicable to the scope
- Stress-stability and intrinsic dissolution rate data, where applicable
Interpretation and conclusions
- Identification and comparison of the forms found
- An opinion on interconversion risk under storage and process conditions
- Discussion of the practical impact on solubility, bioavailability or manufacturability, where applicable
- Evidence organized in a format that supports regulatory submission or intellectual-property discussion
Scope and turnaround
Scope is risk-oriented: the initial assessment defines whether the question requires only form screening or a full forensic comparison with stress testing, avoiding assays that would not change the decision.
- Documentary risk assessment before any bench assay
- Analytical scope adjusted to the question: initial form screening, batch comparison, or intellectual-property dispute
- Methods selected for their ability to discriminate the relevant forms, not from a fixed test list
- Results expressed as form identification, objective comparison and, where applicable, an interconversion risk assessment
- Suited to development screening, process-deviation investigation and intellectual-property dispute support
Frequently asked questions
What is pharmaceutical polymorphism?
- It is the ability of a single chemical compound to arrange itself in more than one crystalline structure, each with its own melting point, solubility and stability, while sharing the same molecular formula. Solvates, hydrates and the amorphous state are related phenomena, with the same practical consequence: different properties arising from the same molecule.
Why does polymorphism matter in drug products?
- Because the API's solid form can determine dissolution rate, bioavailability and product stability over shelf life. A metastable form can spontaneously convert to a more stable form during storage or processing, changing performance with no change to the formulation itself.
What is the difference between polymorphism, crystallinity and amorphous content?
- Polymorphism describes distinct crystalline arrangements of the same molecule. Crystallinity describes the degree of periodic order in the lattice, and amorphous content its absence. A material can be crystalline in a single form, crystalline across multiple polymorphic forms, or carry an amorphous fraction, and each situation calls for a different analytical read.
What happened in the historical ritonavir case?
- In 1998, a new polymorphic form of ritonavir (Form II), more stable and far less soluble than the original form, appeared spontaneously during commercial manufacturing and compromised the product's dissolution, leading to its withdrawal from the market. The case remains an industry reference for the risk of not characterizing and monitoring the solid form across the product lifecycle.
Which techniques identify an API's polymorphic form?
- XRD identifies the diffraction pattern characteristic of each form; DSC and TGA characterize thermal behaviour and distinguish a polymorphic transition from desolvation; microscopy and confocal Raman add morphological and spectral information at particle scale. No single technique is usually sufficient for a robust conclusion.
What is the ICH Q6A decision tree for polymorphism?
- It is a documentary roadmap that determines whether an API needs experimental solid-form characterization, based on whether the compound exhibits known polymorphism, whether the forms have meaningfully different properties, and whether those differences could affect product performance, safety or efficacy.
Do ANVISA and the FDA require solid-form characterization for generics?
- Yes, when the solid form can affect bioavailability or stability. The registration dossier must show that the generic's crystalline form is equivalent to the reference product in the relevant properties, or provide data supporting that a form difference does not compromise bioequivalence.
Does XRD alone confirm which form is present?
- XRD is the most direct technique for crystalline form identification, but samples with low crystallinity, phase mixtures, or low API concentration in a finished product may require DSC, TGA or Raman as confirmation, especially when the result supports a regulatory or intellectual-property decision.
Can polymorphism be analyzed in a finished product, such as a tablet?
- Yes, provided the study design accounts for API dilution in the matrix, excipient signal overlap and each technique's detection limits. Confocal Raman and high-resolution XRD are frequently combined in this scenario.
How does polymorphism relate to intellectual-property disputes?
- A specific crystalline form can be the subject of a patent independent from the parent molecule. Characterizing the form present in a product, your own or a third party's, is often necessary to support or challenge form-specific patent claims and to inform freedom-to-operate decisions.
How long does a polymorphic analysis study take?
- It depends on the scope set after the risk assessment: an initial form screening is faster than a forensic comparison with stress testing and an interconversion study. Turnaround is set in the proposal, after the initial risk assessment.
Is the information submitted handled confidentially?
- Yes. Scope, samples, results and the existence of the study are treated as client confidential information, under a confidentiality agreement signed before samples are sent.
Services that complement polymorphic analysis
Request a proposal
Scope is risk-oriented: the initial assessment defines whether the question requires only form screening or a full forensic comparison with stress testing, avoiding assays that would not change the decision.
Request a proposal